GMPM revoked:

http://www.sec.gov/litigation/admin/2013/34-70582.pdf

GMPM SEC Suspension:

http://www.sec.gov/litigation/suspensions/2013/34-70377.pdf

Order:

http://www.sec.gov/litigation/suspensions/2013/34-70377-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2013/34-70376.pdf

WHAT HAPPENED TO GMPM?? I made a small mint off of this stock 4 years ago with it was trading back and forth between .05 .13??. Now today, I see it is in the tank at .0025. Anybody know what went wrong? Was the company sued? Any info would be appreciated.

Uptrend. Nice!

Here is the response from the CEO...


Hi xxxx,

A priority for Gamma is to come current the SEC and begin full quarterly reports.  In the meantime I may post financials on PINKSHEETS or do a press release on our financials. We are discussing the issue now.  I can say that our authorized shares is 100m and we are well inside that number.  If you have any questions please call. 

 
Best regards and thank you for your support,

 

Joe Cunningham

President

Gamma Pharmaceuticals Inc

(651) 204-2048

barchart.com/quotes/stocks/GMPM

Strong buy! This is looking good.

Only 8% down after a 100% gain in one day.

He sends out emails like APS and the others. His site is:www.pickpennystocks.net

Most of his picks have been dogs for me...bu looks like he did good on this one!

Not bad for a good DD, but SSP on the golden lounge is the best

52 week high by the end of the week!

I sent an email to the CFO and CEo to see the latest financials and stucture, no answer yet...

Who is Michael Stone?

Thanks

GMPM being pumped by Michael Stone because someone who was big at TwinLabs has joined them....

Anyone still in this one?? Thoughts?? Good Luck.

GMPM has made some fast upward moves in the past. keep this one on radar.

.07 - .12 on 30k volume train may be leaving the station?
imo

NEWS: Gamma Pharmaceuticals, Inc., Launches Retail Promotions for Gamma Energy Gel(TM) in New York City and Houston

ST PAUL, Minn., Oct. 24, 2011 /PRNewswire via COMTEX/ -- Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK), a vitamin and nutriceuticals marketing and product formulation company, announced the launch of retail promotions for Gamma Energy Gel(TM) products in the New York metropolitan area and greater Houston markets. Gamma is pleased to announce sampling events in Houston starting this Wednesday, October 26th and couponing events in New York starting Saturday, October 29th, running for one week and again the week of November 19th. Gamma Energy Gels are available in the Duane Reade division of Walgreens in New York and at leading convenience store and independent retail locations in the Houston Metropolitan area.

last 8k - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation
Arrangements of Certain Officers
On September 13, 2011, shareholders holding 52.04% of the outstanding shares of common stock of Gamma Pharmaceuticals Inc. (“Gamma”)
removed Hao Zhang from Gamma’s Board of Directors. The removal did not result from any disagreement between Hao Zheng and the other
Directors of the company. Rather, Hao Zhang had been inactive as a Director of Gamma for some time as a result of Gamma’s deferral of
plans to enter the Chinese market.

Is GMPM registering a pulse? The stock has traded two days in a row.

yeah!!!!!

Activity slowly picking up !!

Last pr: http://www.otcmarkets.com/stock/GMPM/news

Gamma Pharmaceutical GMPM
$.165 $+0.035 +26.92%
Volume: 24,850

GMPM PR Aug 15th

Gamma Pharmaceuticals Inc., Accepts Purchase Orders, Signs Distribution Agreement and Completes Manufacturing Run

Gamma Pharmaceuticals Inc. (NASDAQ: GMPM.PK), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, announced today, the Company accepted purchase orders from three counterparties and expects more in the weeks to come. The Company also signed a distribution agreement for the South-central and the Southwest US market. Importantly, Gamma completed a manufacturing run for its Gamma Energy Gel™, which will be in retail outlets in the New York metropolitan region, Northern California and Texas.

Individually, each of these accomplishments is a noteworthy achievement in the Company's annual plan; collectively, they represent a significant step forward. The Company is utilizing the credit facility announced earlier this year to finance working capital.

About Gamma Pharmaceuticals Inc.

Gamma Pharmaceuticals, Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ nutritional supplements featuring the call to action "You've made a brilliant choice for your nutrition;" SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Gamma Energy Products™ a high performance supplement featuring the call to action, "Get Your Gamma On." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States. Gamma's products utilize proprietary "Gel Delivery Technology®", to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: Gamma Pharmaceuticals Inc.Joe Cunningham, CFO (jcunningham@gammapharma.com)Direct: (651) 204 2048Office: (702) 989 5262

SOURCE Gamma Pharmaceuticals Inc.

Gamma has pps disfunction, the conv financing terms will an important factor imo

GMPM PR July 11

Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting

On July 9, 2011, Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK) ("Gamma" or the "Company") held a Special Shareholders Meeting (the "Meeting") as disclosed in the Company's press release dated June 21, 2011. The June 21, 2011 press release invited shareholders to attend in person or by a special telephone link. The meeting was held at the Bellagio Resort, Las Vegas NV. The agenda for the meeting consisted of a management presentation by the Company's CEO and CFO and an opportunity for the Company's current investors to ask questions. The meeting was attended by Company investors, and a telephone line was made available to those who were unable to attend in person. Management's presentation consisted of an operational and financial review of the past four years and outlined a plan to move the Company forward in the months and years ahead. The Meeting was informational only, and no shareholder vote was taken on any issue. The principal operational highlight was the announcement that Gamma Gel product was now in the process of going on the shelves of a major Pharmacy chain in the New York metropolitan area. The financial review provided a general summary of cash expenditures versus money raised from investors, of which approximately $4,000,000 had been invested to date in the business. As the Company's last Form 10-Q filing with the Securities and Exchange Commission was for the quarter ending September 30, 2009, certain financial information was disclosed subsequent to the Company's last Form 10-Q filing. Specifically, the Company had arranged for a $150,000 revolving off-balance sheet factoring line with an existing investor to fund Company inventory and accounts receivable. Approximately $30,000 had been drawn down on this line so far to pay for product manufacturing and shipping. In addition, a Term Sheet has been arranged with an investor group for $1,400,000 in convertible debt financing. Upon closing of this facility, it is intended that the first $200,000 will be used to bring current the Company's SEC filings, with the remainder of the line to be used to provide working capital. Management stressed the fact that financing was now available to begin to bring the Company's products to market, and that Management and investors should be more interested in results on a monthly and quarterly basis than on longer range financial forecasts. The Company undertook to host conference calls or webinars on a more frequent basis so that shareholders, potential investors and market participants will have greater visibility into the Company on a regular basis. The Company also provided sample products to those attending the meeting. Those wishing additional information on the Meeting may contact the Company's CFO, Joseph Cunningham at jcunningham@gammapharma.com or at (651) 204-2048.

About Gamma Pharmaceuticals Inc

Gamma Pharmaceuticals, Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ nutritional supplements featuring the call to action "You've made a brilliant choice for your nutrition;" SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Gamma Energy Products™ high performance supplements featuring the call to action, "Get your Gamma On." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States. Gamma's products utilize proprietary "Gel Delivery Technology®", to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, convenience and great taste. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: Gamma Pharmaceuticals, Inc.Joe Cunningham, CFO (jcunningham@gammapharma.com)Direct: (651) 204 2048Office: (702) 989 5262

SOURCE Gamma Pharmaceuticals, Inc.

The company must have drank their own energy gel and is trying to wake up

GMPM PR June 27, 2011

Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain

Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally, announced today, the Company has completed a sale and revenue collection cycle with a major pharmacy retail chain. Gamma shipped the Company's energy gel products to a Northeast distribution center for delivery to retail outlets in the New York metropolitan area. The retail chain has more than 8,000 outlets nationwide. Gamma's CEO Peter Cunningham noted, "Over the past 2 years, the retail pharmacy sector absorbed the effect of the economic crisis and has started to recover. With the sector's recovery underway, we have seen renewed interest in Gamma's new technologies and brands nationwide. This interest is paralleled in the supermarket and convenience store channels." He continued, "the credit facility announced in our June 8th 2011 press release will help us fill more orders and address many other retail opportunities."

About Gamma Pharmaceuticals, Inc.

Gamma Pharmaceuticals, Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ nutritional supplements featuring the call to action "You've made a brilliant choice for your nutrition;" SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Gamma Energy Products™ a high performance supplement featuring the call to action, "Get Your Gamma On." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States. Gamma's products utilize proprietary "Gel Delivery Technology®", to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: Gamma Pharmaceuticals, Inc.Joe Cunningham, CFO (jcunningham@gammapharma.com)Direct: (651) 204 2048Office: (702) 989 5262

SOURCE Gamma Pharmaceuticals, Inc.

Just my two cents here but GMPM needs new writers for the PR's.

GMPM PR June 21 2011

Gamma Pharmaceuticals, Inc. Announces Special Shareholders Meeting
Gamma Pharmaceuticals (PN) (USOTC:GMPM)

Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK), ("Gamma" or the "Company",) a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally, announced a special meeting for its shareholders.

TO OUR STOCKHOLDERS:

Over the past few months, in particular, we have had numerous phone calls from stockholders stating their obvious concerns over the lack of ongoing communication regarding our Company's progress and the overall performance of our Common Stock. These two factors have led many of those with whom we have spoken to express concern over the overall "health" of our company and its prospects in this difficult economic environment.

To that end, Gamma's Board of Directors (the "Board") have organized a Special Shareholders Meeting on July 9, 2011 commencing at 1:00pm at the Bellagio Resort, Las Vegas.

The purpose of the meeting is to provide a forum for Gamma's current investors to discuss the direction of the Company in the months ahead and to review Gamma's recent operating history, reflecting the Company's effort to enhance investor communications. Each participant will require a ticket to gain entrance to the meeting and a dial-in number can be made available. Those wishing to attend or to participate by conference call may contact Gamma's CFO, Joseph Cunningham at (651) 204-2048 or by email at jcunningham@gammapharma.com

The recent past has been challenging for Gamma, but the Company has begun to clear the road ahead of most obstacles and Board looks forward to an open and candid discussion on Gamma's future. The Board is grateful to Gamma's investors as the Company continues the journey upon which we embarked. The Board of Directors looks forward to having a good turnout on July 9th and we thank you in advance for your participation in this important meeting.

Best regards,

The Board of Directors, Gamma's Pharmaceuticals, Inc.

SOURCE Gamma Pharmaceuticals, Inc.

This is a Vegas based company, next time out there Im stopping in!

Gamma Pharmaceuticals is: "Firing On All Cylinders!"

Its only 2pm. and the volume is 10x yesterdays. Wow!!

I hear were going for $10 in trading tomorrow! I think GMPM needs some Jugular® Energy Drink! -- "Go for the Jugular!

Flat not enough $$ for glossy
imo

It was high end paint for the close. Likely Montana Gold Spray Paint Cans. lol

$7.00 worth of trading, must have had a coupon!

Caution Reading: There are approximately 63-million common shares outstanding with management controlling approximately 53% of the outstanding stock. No stock has been issued in nearly 18-months; but stock will be issued in conjunction with deployment of the Credit Facility.

GMPM News June 7, 2011

Gamma Pharmaceuticals Inc. Outlines Recent Achievements and Near Term Objectives -- Gamma Gets Traction

Gamma Pharmaceuticals, Inc. (PINKSHEETS: GMPM), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally.

Gamma's management is pleased to communicate our recent developments and to provide important information to our shareholders on our progress, as the company gains commercial traction. Please note the following:

Sales and Distribution Achievements

Gamma began shipping products to a major national retail chain in April, and is working with their management to put in place additional orders for +/- 8000 outlets. Gamma can strategically launch products in this chain's outlets by region, providing the Company with a more cost-effective path into a major national account.

Gamma just appointed distributors to service territories in California, Texas and selected locations in the Southeastern US. These distributors have placed pro-forma orders for Gamma energy products and are awaiting completion of a manufacturing run currently underway. Negotiations continue with other distributors in several territories across the US.

Gamma's relationship with the Company's major distributor, announced last year, remains intact. They have waited patiently while Gamma management has worked to put in place production financing arrangements sufficient to meet the unit forecasts agreed and the roll-out marketing programs.

Last month, Gamma signed a contract for export sales and is awaiting receipt of a 50% deposit. Contract terms call for a deposit paid to Gamma of 50% of the value of the order with full payment due at completion of manufacture, prior to shipment. Gamma has received the sales order documentation and is waiting for the deposit to commence manufacturing. Management has several other export negotiations underway.

Production Financing to support Sales and Distribution Achievements

Gamma has just negotiated a private production financing arrangement ("Credit Facility") with one of the Company's trusted shareholders. This non-exclusive, off-balance-sheet vehicle can initially provide the Company with the operational liquidity necessary to fund inventory and to meet current expenses. Distributors have recently placed pro-forma purchase orders and inventory reservations with Gamma; Gamma has utilized the Credit Facility to pay suppliers. Manufacturing is now underway to meet these orders.

Current Focus

Gamma's focus is narrow and it is specific: sales, manufacturing and financing. The product pipeline is fully developed and has been revised sufficiently to attract retailers, distributors and consumers. Closely working with distributors and retailers to continue product rollout should achieve in-market sales sufficient to fund the brand marketing programs. The Company's Credit Facility will fund product production and meet working capital needs.

Financing

Traditional equity financing has not been available, despite Management's best efforts. Gamma is diligently working with a variety of parties to secure financing and improve the Company's balance sheet. There are approximately 63-million common shares outstanding with management controlling approximately 53% of the outstanding stock. No stock has been issued in nearly 18-months; but stock will be issued in conjunction with deployment of the Credit Facility.

Audit, SEC Filings and Shareholder Meeting

Coming current with Audit and SEC filings is one of Management's top priorities. Gamma has continued to operate the business as if it were audit compliant. The audit process will be funded by current cash flow from product sales. Due to the low-level of commercial activity these past two years, no substantial audit issues are expected. The company intends to come current with its SEC filings and hold an annual general meeting later this year.

Other Developments

Gamma is moving forward with its own branded energy products. Gamma is now procuring orders and manufacturing its own range of energy products under the Gamma Energy brand. Gamma watchers may recall the Company converting its licensing agreement for energy products with Jugular Inc., into a joint venture last year. This joint venture has not performed as expected. Jugular Inc. has a vision and is trying to create an image for the brand that Management has determined does not resonate well with Gamma's target audience. A dispute has arisen and the arrangement has been sidelined. In addition, in 2010, the Company announced a global product development and marketing joint venture with a world famous athletic personality. This joint venture also has also not performed to either party's expectations and ended amicably earlier this year.

As Gamma gains commercial traction, Management continues to work diligently to source sales opportunities and to develop the Company to meet investors' expatiations. Management believes that the Company has gained a foothold into a key retail channel. This traction, when combined with other distributors and retail opportunities, can provide a growth profile consistent with Gamma's peers. Management will seek closer communication with investors and stakeholders but otherwise invites inquiries to the Company's corporate headquarters.

About Gamma Pharmaceuticals Inc

Gamma Pharmaceuticals, Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ nutritional supplements featuring the call to action "You've made a brilliant choice for your nutrition"; SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy"; and, Gamma Energy Products™ a high performance supplements featuring the call to action, "Get your Gamma On." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present, Gamma manufactures in North America and distributes in the United States. Gamma's products utilize proprietary "Gel Delivery Technology®" to create innovative gel product forms that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:

Gamma Pharmaceuticals Inc

Joe Cunningham
CFO
jcunningham@gammapharma.com
Direct: (651) 204 2048
Office: (702) 989 5262

GMPM +.03 Ultra Man time

Gamma seems to need a blast of Gamma, ..

You da man StockMD

MICHAEL COHEN Officer / Director
940 SWEETWATER LANE STE 512A
BOCA RATON FL 33431 US

EURO TREND TRADER INC. Is listed as INACTIVE in Florida Sec. of State

Euro Trend trader :http://sunbiz.org/scripts/cordet.exe?action=DETFIL&inq_doc_number=P07000045946&inq_came_from=NAMFWD&cor_web_names_seq_number=0000&names_name_ind=N&names_cor_number=&names_name_seq=&names_name_ind=&names_comp_name=EUROTRENDTRADER&names_filing_type=

5/10/2009 ,Euro Trend Trader, Inc. ("EuroTrend"), which provided that EuroTrend would provide non-exclusive consulting services to us including: (i) the introduction of Gamma to: potential funding sources, market makers and new strategic relationships and (ii) investor relations support. In return for these services, we agreed to pay EuroTrend: (i) a cash fee of $10,000, (ii) a $3,000 monthly retainer, (iii) 500,000 shares of our restricted stock and (iv) a finder's fee, upon the closing a financing based upon a funding source introduced by EuroTrend, consisting of a 2% cash fee and, for direct equity investments – a 10% cash fee form monies raised up to $100,000 and 15% for monies raised from $100,000 to $1,000,000 and 10% again on monies raised above 1,000,000. The agreement with EuroTrend had a term of six (6) months.

DD:4/6/2009, Atlanta Capital Partners, LLC (“ACP”), wherein we engaged ACP as our Strategic Corporate Advisor.

This stock is like a Vegas Crap Shoot!, re-initiating fresh DD !

GMPM green this morning, this is overdue for big news

Unless you pay the $10 it will always read not in good standing on the Delaware SOS site.. Kinda deceptive if you ask me...

Delaware registration.
I did not pay for status.
May call Agent. Can't today because it is Saturday.

https://delecorp.delaware.gov/tin/controller

Entity Details THIS IS NOT A STATEMENT OF GOOD STANDING
File Number: 2325436 Incorporation Date / Formation Date: 02/10/1993
(mm/dd/yyyy)
Entity Name: GAMMA PHARMACEUTICALS INC.
Entity Kind: CORPORATION Entity Type: GENERAL
Residency: DOMESTIC State: DE

REGISTERED AGENT INFORMATION

Name: CORPORATION SERVICE COMPANY
Address: 2711 CENTERVILLE ROAD SUITE 400
City: WILMINGTON County: NEW CASTLE
State: DE Postal Code: 19808
Phone: (302)636-5401

Additional Information is available for a fee. You can retrieve Status for a fee of $10.00 or
more detailed information including current franchise tax assessment, current filing history
and more for a fee of $20.00.

Anybody in Vegas able to do a drop in?